10-QPeriod: Q3 FY2021

DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2021

Filed October 28, 2021For Securities:DXCM

Summary

DexCom, Inc. reported a solid third quarter of 2021, with revenues reaching $650.2 million, a significant 30% increase year-over-year. This growth was primarily driven by strong sales volume of their disposable sensors, reflecting continued expansion of their global customer base. The company also demonstrated improved profitability, with gross profit rising 31% to $446.9 million and operating income increasing by 26% to $118.3 million. Despite a slight dip in net income to $70.9 million (down 2%), the company's financial health remains robust, with total assets growing to $4.78 billion and stockholders' equity increasing to $2.14 billion. The company continues to invest heavily in research and development, with R&D expenses up 47% year-over-year, indicating a commitment to future product innovation. Financially, DexCom ended the period with a strong liquidity position, holding $1.44 billion in cash and cash equivalents, and $1.25 billion in short-term marketable securities, totaling $2.70 billion. Cash flow from operations was healthy at $336.7 million for the nine months ended September 30, 2021. The company also managed its debt effectively, with convertible notes outstanding but no borrowings against its revolving credit facility. Overall, the report showcases continued top-line growth supported by operational efficiencies and a strong balance sheet, positioning DexCom favorably for future expansion.

Financial Statements
Beta
Revenue$650.20M
Cost of Revenue$203.30M
Gross Profit$446.90M
R&D Expenses$128.80M
SG&A Expenses$198.50M
Operating Expenses$328.60M
Operating Income$118.30M
Interest Expense$4.60M
Net Income$87.30M
EPS (Basic)$0.23
EPS (Diluted)$0.21
Shares Outstanding (Basic)387.40M
Shares Outstanding (Diluted)430.30M

Key Highlights

  • 1Revenue increased by 30% year-over-year to $650.2 million for the third quarter of 2021, driven by increased sales volume of disposable sensors.
  • 2Gross profit grew by 31% to $446.9 million, and gross profit margin improved to 68.7% from 68.0% in the prior year's quarter.
  • 3Operating income increased by 26% to $118.3 million, reflecting strong sales growth and management of operating expenses.
  • 4Net income for the third quarter was $70.9 million, a slight decrease of 2% from the prior year, impacted by higher operating expenses and interest expense.
  • 5Diluted earnings per share were $0.71, a decrease from $0.73 in the same period last year.
  • 6The company maintained a strong liquidity position with $2.70 billion in cash, cash equivalents, and short-term marketable securities as of September 30, 2021.
  • 7Research and development expenses significantly increased by 47% year-over-year to $128.8 million, indicating substantial investment in future growth and innovation.

Frequently Asked Questions

DexCom reported revenue of $650.2 million for the third quarter of 2021, marking a substantial 30% increase compared to the same period in the previous year. This growth was primarily attributed to increased sales volume of their disposable sensors, reflecting ongoing expansion of their customer base.

Profitability showed positive trends, with gross profit increasing by 31% to $446.9 million, leading to an improved gross profit margin of 68.7%. Operating income also rose by 26% to $118.3 million. While net income saw a slight decrease of 2% to $70.9 million, and diluted EPS fell to $0.71 from $0.73, the overall operational performance remained strong due to increased revenues and operational efficiencies.

DexCom maintained a robust liquidity position as of September 30, 2021, with $1.44 billion in cash and cash equivalents and $1.25 billion in short-term marketable securities, totaling $2.70 billion. The company also had $193.6 million available under its revolving credit facility and no outstanding borrowings, indicating strong financial flexibility.

The company significantly increased its investment in the future by raising Research and Development (R&D) expenses by 47% year-over-year to $128.8 million in the third quarter of 2021. This increased investment underscores DexCom's commitment to product innovation and maintaining a competitive edge in the continuous glucose monitoring market.